Pharma recruiting is broken—at least when it comes to how most teams “find” talent.
They search for titles. They scan résumés. They ask for the same buzzwords. And they miss the real signal: who has actually shaped the science behind the next wave of d…

Pharma has a familiar playbook: take an old drug, reframe it as “new,” and price it like it’s never been treated before.
That’s the core tension behind the latest debate highlighted in DrugPatentWatch’s piece on how companies justify premium pricing fo…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s drug strategy is often described in headlines as a “self-reliance” push. But the real story is hiding in plain sight: patent filings.
In a world where supply chains are fragile and regulatory timelines are opaque, the most reliable early-warni…

Europe’s patent system is supposed to be a referee—clear rules, final calls, and predictable outcomes. But lately, it’s been looking more like a maze: big pharma can keep generics waiting by steering disputes into procedural limbo, where “eventual” dec…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a $5M decision—if you design the strategy before the first complaint is filed.
That’s the core message behind a new playbook from DrugPatentWatch: cutting the cost of pate…

PBMs and rebates are no longer “back-office” topics. They’re board-level risk.
If you’re a pharma executive—commercial, strategy, finance, or legal—your next earnings cycle may hinge less on your pipeline slide and more on what happens after launch: fo…

Mark Cuban’s “cost-plus” pricing isn’t just a pricing tweak—it’s a direct challenge to the patent playbook that’s defined Big Pharma for decades.
For years, the industry’s story has been consistent: innovation is expensive, patents are necessary to rec…

Most founders treat a provisional patent like a seatbelt: something you put on early, forget about, and hope you never need.
But in drug development, “early” isn’t a vibe—it’s a strategy. And a provisional filing isn’t a placeholder. It’s a legal instr…

Don’t Wait for the Patent Cliff: Build Pharmaceutical Supply-Chain Resilience Years Before Expiration
The patent cliff isn’t a cliff you can see from the road. It’s a slow-motion event—one that starts long before the last day of exclusivity. And when i…